☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
BridgeBio
bridgebio Reports the Results for Acoramidis in P-III Trial for the Treatmnet of Transthyretin Amyloid Cardiomyopathy
January 11, 2024
BridgeBio Collaborated with Resilience to Manufacture and Advance BBP-812 for Canavan Disease and BP-631 for Congenital Adrenal Hy...
October 5, 2023
BridgeBio Presents P-III Study (ATTRibute-CM) Results of Acoramidis for Transthyretin Amyloid Cardiomyopathy at ESC 2023
August 28, 2023
BridgeBio, Sentynl, and Medison Reports the Approval of Nulibry in Israel for the Treatment of Molybdenum Cofactor Deficiency Type...
August 12, 2022
BridgeBio Reports Results of BBP-812 in the P-I/II (CANaspire) Trial for the Treatment of Canavan Disease
June 23, 2022
Bridgebio Entered into an Exclusive License Agreement with BMS to Develop and Commercialize BBP-398 for the Treatment of Cancer
May 13, 2022
Load more...
Back to Home